Topic: patent expirations
One of AbbVie’s Humira patents bit the dust late Tuesday, marking a win for copycats. But they still have a long way to go before they’ll really be able to celebrate.
Pfizer could have a challenging year on the patent loss front, starting with the generics of its antidepressant Pristiq now hitting the market.
Eli Lilly, Pfizer, Takeda, Bristol-Myers Squibb and Gilead are set to hit the patent cliff this year with some of their respective big-sellers.
AstraZeneca’s aging respiratory giant Symbicort won a coveted pediatric exclusivity nod from the FDA, putting it in line for hundreds of millions in additional brand sales.
Hiking prices on older meds to prod patients toward newer ones is a time-honored pharma tactic. And Gilead Sciences is using it, now that it has launched a new generation of HIV fighters.
The Delhi High Court has told Pfizer to withdraw its inflammatory and allergy drug Medrol from the Indian market half a year before its patent expiration date.